Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas

Conditions:   Adenocarcinoma of the Stomach;   Adenocarcinoma of the Gastroesophageal Junction
Interventions:   Combination Product: Regorafenib and Irinotecan;   Drug: Irinotecan
Sponsor:   UNICANCER
Not yet recruiting

https://ift.tt/2AsBt07